FinancialBuzz.com’s latest
The Buzz
Show: Featuring Our Corporate News Recap on “Entera Bio Ltd. Announces Positive Topline Phase 2 BMD Data for EB613”
Entera Bio Ltd. (NASDAQ: ENTX)
surged over 59% in premarket trading after the company announced the final 6-month bone mineral density results from the completed Phase 2 clinical trial of EB613 for the treatment of osteoporosis.
The study’s primary efficacy endpoint, a statistically significant increase in P1NP at 3 months was achieved while EB613 exhibited an excellent safety profile, with no drug related serious adverse events and is positioned to be the first oral bone building agent for the treatment of osteoporosis.
Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company’s proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company’s most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc.
For more information, please visit:
Entera Bio Ltd.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.
The post
“The Buzz” Show: Entera Bio Ltd. (NASDAQ: ENTX) Topline Phase 2 BMD Data for EB613
first appeared on
Financial Buzz
.
For further details see:
“The Buzz” Show: Entera Bio Ltd. (NASDAQ: ENTX) Topline Phase 2 BMD Data for EB613